SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”

It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.